"We were pleased with our fourth-quarter and full-year 2022 financial performance, highlighted by revenue growth of 14% and 17%, respectively, when excluding contributions from REGEN-COV and Ronapreve, demonstrating the commercial strength and increasing diversity of our business," said Robert E. Landry, Executive Vice President, Finance and CFO of Regeneron. "In January 2023, our Board of Directors authorized a new $3.0 billion share repurchase program, enabling us to continue returning capital directly to shareholders. This year, we look forward to driving long-term shareholder value through continued investment in R&D, excellent commercial execution and strategic business development."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron Posts Q4 Beat; Shares Rise
- Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
- Regeneron Announces Investor Conference Presentations
- Regeneron upgraded at Cowen with Eylea ‘secure’ and pipeline ‘delivering’
- Regeneron upgraded to Outperform from Market Perform at Cowen
